Piclozotan is an investigational drug that may offer a unique opportunity for Parkinson's disease patients to optimize their levodopa therapy, by controlling both dyskinesia and OFF Time in patients experiencing motor complications associated with their levodopa use.
Click here to find out more!
Asubio Pharmaceuticals, Inc. is an early stage clinical development company focusing on adding value to the novel new chemical entities and biologics discovered in its parent’s research facilities in Japan.
Leveraging the expertise of a small number of highly talented and motivated specialists with a culture of cooperation and team work, Asubio is working everyday toward building a brighter, healthier tomorrow.